PKBO — Peak Bio Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.52m
- $9.33m
- $0.37m
Annual income statement for Peak Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0.528 | 0.608 | 0.368 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 13.3 | 8.73 | 12.9 | 13.4 |
| Operating Profit | -13.3 | -8.2 | -12.3 | -13.1 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -13.3 | -8.21 | -13.2 | -12.8 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -13.3 | -8.29 | -13.1 | -12.8 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -13.3 | -8.29 | -13.1 | -12.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -13.3 | -8.29 | -13.1 | -12.8 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.615 | -0.408 | -0.589 | -0.439 |